Skip to main content
Top
Published in: Current Diabetes Reports 10/2014

01-10-2014 | Diabetes and Other Diseases-Emerging Associations (JJ Nolan, Section Editor)

The Epidemiology of Diabetes and Cancer

Authors: Bendix Carstensen, Marit Eika Jørgensen, Søren Friis

Published in: Current Diabetes Reports | Issue 10/2014

Login to get access

Abstract

The literature on cancer occurrence in persons with diabetes has almost invariably been concerned with relative measures. In this paper, we briefly review this, but the aim is to quantify the absolute occurrence of diabetes and cancer in the population in order to give a fuller picture, which also includes the competing mortality risk. Overall, we find that some 35 % of the population will have a diagnosis of diabetes in their lifetime, 44 % a diagnosis of cancer, and about 15 % will have both diagnoses. The impact of differing mortality between persons with and without diabetes is illustrated by the fact that a person without diabetes at age 50 has a smaller lifetime risk of cancer than a person aged 50 with diabetes. Thus, the differences in cancer occurrence between persons with and without diabetes are of quantitatively smaller importance than the differences in mortality.
Literature
1.
go back to reference Adami HO, McLaughlin J, Ekbom A, Berne C, Silverman D, Hacker D, et al. Cancer risk in patients with diabetes mellitus. Cancer Causes Control. 1991;2:307–14.PubMedCrossRef Adami HO, McLaughlin J, Ekbom A, Berne C, Silverman D, Hacker D, et al. Cancer risk in patients with diabetes mellitus. Cancer Causes Control. 1991;2:307–14.PubMedCrossRef
2.
go back to reference Wideroff L, Gridley G, Mellemkjær L, Chow WH, Linet M, Keehn S, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst. 1997;89:1360–5.PubMedCrossRef Wideroff L, Gridley G, Mellemkjær L, Chow WH, Linet M, Keehn S, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst. 1997;89:1360–5.PubMedCrossRef
3.
go back to reference Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004;159:1160–7.PubMedCrossRef Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004;159:1160–7.PubMedCrossRef
4.
go back to reference Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdottir S, Steineck G. Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden. Diabetologia. 2009;52:1745–54.PubMedCrossRef Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdottir S, Steineck G. Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden. Diabetologia. 2009;52:1745–54.PubMedCrossRef
5.
go back to reference HM Colhoun the SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia. 2009;52:1755–65.CrossRef HM Colhoun the SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia. 2009;52:1755–65.CrossRef
6.
go back to reference Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52:1766–77.PubMedCrossRef Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52:1766–77.PubMedCrossRef
7.
go back to reference Hemkens LG, Grouven U, Bender R, Günster C, Gutschmidt S, Selke GW, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009;52:1732–44.PubMedCrossRefPubMedCentral Hemkens LG, Grouven U, Bender R, Günster C, Gutschmidt S, Selke GW, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009;52:1732–44.PubMedCrossRefPubMedCentral
8.••
go back to reference Andersson C, Vaag A, Selmer C, Schmiegelow M, Sørensen R, Lindhardsen J, et al. Risk of cancer in patients using glucose-lowering agents: a nationwide cohort study of 3.6 million people. BMJ Open 2012; 2(3). The only study which comprises the entire population in evaluation of possible drug effects on cancer occurrence in persons with diabetes, and therefore the only study of drug effects not potentially biased by selection of subgroups of patients. The study only analyses occurrence of all cancers, not specific sites of cancer. It shows that the risk of cancer is elevated shortly after initiation of (any) therapy, but not in the long run. Andersson C, Vaag A, Selmer C, Schmiegelow M, Sørensen R, Lindhardsen J, et al. Risk of cancer in patients using glucose-lowering agents: a nationwide cohort study of 3.6 million people. BMJ Open 2012; 2(3). The only study which comprises the entire population in evaluation of possible drug effects on cancer occurrence in persons with diabetes, and therefore the only study of drug effects not potentially biased by selection of subgroups of patients. The study only analyses occurrence of all cancers, not specific sites of cancer. It shows that the risk of cancer is elevated shortly after initiation of (any) therapy, but not in the long run.
9.•
go back to reference Carstensen B, Witte DR, Friis S. Cancer occurrence in Danish diabetic patients: duration and insulin effects. Diabetologia. 2012;55(4):948–58. The largest study of cancer occurrence among persons with diabetes. The study takes duration of diabetes into account and shows that risk is highest shortly after diagnosis of diabetes. Also includes analysis by cancer site and insulin use.PubMedCrossRef Carstensen B, Witte DR, Friis S. Cancer occurrence in Danish diabetic patients: duration and insulin effects. Diabetologia. 2012;55(4):948–58. The largest study of cancer occurrence among persons with diabetes. The study takes duration of diabetes into account and shows that risk is highest shortly after diagnosis of diabetes. Also includes analysis by cancer site and insulin use.PubMedCrossRef
10.•
go back to reference Johnson JA, Bowker SL, Richardson K, Marra CA. Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia. 2011;54:2263–71. The first study to systematically include duration of diabetes as an important determinant of the cancer risk among persons with diabetes. Shows that the risk of cancer is highest shortly after diagnosis of cancer, and inversely related to frequency of GP contact before diabetes diagnosis.PubMedCrossRef Johnson JA, Bowker SL, Richardson K, Marra CA. Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia. 2011;54:2263–71. The first study to systematically include duration of diabetes as an important determinant of the cancer risk among persons with diabetes. Shows that the risk of cancer is highest shortly after diagnosis of cancer, and inversely related to frequency of GP contact before diabetes diagnosis.PubMedCrossRef
11.
go back to reference Ranc K, Jørgensen ME, Friis S, Carstensen B. Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment. Diabetologia. 2014;57(5):927–34.PubMedCrossRef Ranc K, Jørgensen ME, Friis S, Carstensen B. Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment. Diabetologia. 2014;57(5):927–34.PubMedCrossRef
12.
go back to reference Renehan AG, Yeh HC, Johnson JA, Wild SH, Gale EA, Møller H. The Diabetes and Cancer Research Consortium. Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia. 2012;55(6):1619–32.PubMedCrossRef Renehan AG, Yeh HC, Johnson JA, Wild SH, Gale EA, Møller H. The Diabetes and Cancer Research Consortium. Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia. 2012;55(6):1619–32.PubMedCrossRef
13.
go back to reference Sasazuki S, Charvat H, Hara A, Wakai K, Nagata C, Nakamura K, et al. Diabetes mellitus and cancer risk: pooled analysis of eight cohort studies in Japan. Cancer Sci. 2013;104(11):1499–507.PubMedCrossRef Sasazuki S, Charvat H, Hara A, Wakai K, Nagata C, Nakamura K, et al. Diabetes mellitus and cancer risk: pooled analysis of eight cohort studies in Japan. Cancer Sci. 2013;104(11):1499–507.PubMedCrossRef
14.
go back to reference Kajüter H, Geier AS, Wellmann I, Krieg V, Fricke R, Heidinger O, et al. Kohortenstudie zur Krebsinzidenz bei Patienten mit Diabetes mellitus Typ 2. Bundesgesundheitsblatt. 2014;57:52–9.CrossRef Kajüter H, Geier AS, Wellmann I, Krieg V, Fricke R, Heidinger O, et al. Kohortenstudie zur Krebsinzidenz bei Patienten mit Diabetes mellitus Typ 2. Bundesgesundheitsblatt. 2014;57:52–9.CrossRef
15.
go back to reference Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 2008;300:2754–64.PubMedCrossRefPubMedCentral Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 2008;300:2754–64.PubMedCrossRefPubMedCentral
16.
go back to reference Carstensen B, Christensen JK, Marcussen MM, Borch-Johnsen K. The national diabetes register. Scand J Public Health. 2011;39(7 suppl):58–61.PubMedCrossRef Carstensen B, Christensen JK, Marcussen MM, Borch-Johnsen K. The national diabetes register. Scand J Public Health. 2011;39(7 suppl):58–61.PubMedCrossRef
17.
go back to reference Carstensen B, Kristensen JK, Ottosen P, Borch-Johnsen K. The Danish national diabetes register: trends in incidence, prevalence and mortality. Diabetologia. 2008;51:2187–219.PubMedCrossRef Carstensen B, Kristensen JK, Ottosen P, Borch-Johnsen K. The Danish national diabetes register: trends in incidence, prevalence and mortality. Diabetologia. 2008;51:2187–219.PubMedCrossRef
18.
20.
go back to reference Carstensen B. Age-period-cohort models for the Lexis diagram (author’s reply). Stat Med. 2007;27:1561–4.CrossRef Carstensen B. Age-period-cohort models for the Lexis diagram (author’s reply). Stat Med. 2007;27:1561–4.CrossRef
21.•
go back to reference Johnson JA, Carstensen B, Witte D, Bowker SL, Lipscombe L, Renehan AG, et al. Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia. 2012;55(6):1607–18. This paper discusses the methodological aspects of epidemiological evaluation of cancer risk in persons with and without diabetes, and proposes guidelines for this type of studies, particularly in relation to possible drug effects.PubMedCrossRef Johnson JA, Carstensen B, Witte D, Bowker SL, Lipscombe L, Renehan AG, et al. Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia. 2012;55(6):1607–18. This paper discusses the methodological aspects of epidemiological evaluation of cancer risk in persons with and without diabetes, and proposes guidelines for this type of studies, particularly in relation to possible drug effects.PubMedCrossRef
Metadata
Title
The Epidemiology of Diabetes and Cancer
Authors
Bendix Carstensen
Marit Eika Jørgensen
Søren Friis
Publication date
01-10-2014
Publisher
Springer US
Published in
Current Diabetes Reports / Issue 10/2014
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-014-0535-8

Other articles of this Issue 10/2014

Current Diabetes Reports 10/2014 Go to the issue

Lifestyle Management to Reduce Diabetes/Cardiovascular Risk (EM Venditti, Section Editor)

Lifestyle Management for Enhancing Outcomes after Bariatric Surgery

Lifestyle Management to Reduce Diabetes/Cardiovascular Risk (EM Venditti, Section Editor)

Weight Loss and Physical Activity for Disease Prevention in Obese Older Adults: an Important Role for Lifestyle Management

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.